← 홈

Antibody · 황반변성·망막

19개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 19개
AntibodySHOTFDACuratedFDABiologicRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 66.4%임상시험 163상태 APPROVED
AntibodySHOTFDACuratedFDABiologicRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 68%임상시험 147상태 APPROVED
AntibodyJanssenderuxtecan in ovarian cance…Phase 3

infliximab (Remicade, Remicade (infliximab))

Uveitis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#인기#항체+5
임상시험 62상태 ACTIVE
AntibodystaleRochePhase 3

Active bevacizumab and Active dexamethasone (Active bevacizumab and Active dexamethasone)

Non-Ischemic Central Retinal Vein Occlusion · Non-Ischemic Central Retinal Vein Occlus

#Non-IschemicCentralRetinalVeinOc#Antibody#Phase3#항체#면역항체+2
효능 ORR 16.2%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

ranibizumab (Lucentis, Bevacizumab, Ranibizumab)

Retinopathy of Prematurity Both Eyes · Retinopathy of Prematurity Both Eyes

#RetinopathyofPrematurityBothEyes#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNational Eye Institute (NEI)Phase 1

Zenapax (Daclizumab, Daclizumab (Zenapax))

Uveitis · Uveitis

#Uveitis#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Faricimab (Faricimab)

Age-Related Macular Degeneration; Diabetic Macular Edema · Non-Proliferative Diabetic Retinopathy

#Non-ProliferativeDiabeticRetinop#Antibody#Phase3#항체#면역항체+4
효능 ORR 16.9%임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleSaglik Bilimleri UniversitesiPreclinical

ranibizumab (Lucentis, dexamethasone implant versus ranibizumab)

Diabetic Macular Edema; Inflammation · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleHawaii Pacific HealthPhase 2

ranibizumab (Lucentis, high-dose ranibizumab)

PCV; Polypoidal Choroidal Vasculopathy · PCV

#PCV#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

injection Combined Bevacizumab and Fasudil (injection Combined Bevacizumab and Fasudil)

Retinal Vein Occlusion · Retinal Vein Occlusion

#RetinalVeinOcclusion#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

injection bevacizumab (injection bevacizumab)

Retinal Vein Occlusion · Retinal Vein Occlusion

#RetinalVeinOcclusion#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab (injection of bevacizumab)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleShahid Beheshti University of M…Phase 3

injection of bevacizumab and erythropoietin (injection of bevacizumab and erythropoietin)

Refractory Diabetic Macular Edema · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleDan LiangPhase 2

adalimumab (Humira, reduction or discontinuation of Adalimumab)

Uveitis; Adalimumab · Uveitis

#Uveitis#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleGenentech, Inc.Phase 3

ranibizumab (rhuFab V2, rhuFab V2 (ranibizumab))

Macular Degeneration · Macular Degeneration

#MacularDegeneration#Antibody#Phase3#항체#면역항체+2
효능 ORR 56.4%임상시험 1상태 ACTIVE